330 related articles for article (PubMed ID: 28428708)
61. Postoperative therapy options for hepatocellular carcinoma.
Zhong JH; Ma L; Li LQ
Scand J Gastroenterol; 2014 Jun; 49(6):649-61. PubMed ID: 24716523
[TBL] [Abstract][Full Text] [Related]
62. Hepatitis virus infection affects DNA methylation in mice with humanized livers.
Okamoto Y; Shinjo K; Shimizu Y; Sano T; Yamao K; Gao W; Fujii M; Osada H; Sekido Y; Murakami S; Tanaka Y; Joh T; Sato S; Takahashi S; Wakita T; Zhu J; Issa JP; Kondo Y
Gastroenterology; 2014 Feb; 146(2):562-72. PubMed ID: 24184133
[TBL] [Abstract][Full Text] [Related]
63. Challenges in cancer vaccine development for hepatocellular carcinoma.
Buonaguro L; Petrizzo A; Tagliamonte M; Tornesello ML; Buonaguro FM
J Hepatol; 2013 Oct; 59(4):897-903. PubMed ID: 23714157
[TBL] [Abstract][Full Text] [Related]
64. Hepatocellular carcinoma in Saudi Arabia: role of hepatitis B and C infection.
Ayoola EA; Gadour MO
J Gastroenterol Hepatol; 2004 Jun; 19(6):665-9. PubMed ID: 15151622
[TBL] [Abstract][Full Text] [Related]
65. Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection.
Tajiri K; Baba H; Kawai K; Minemura M; Yasumura S; Takahara T; Sugiyama T
J Gastroenterol Hepatol; 2016 Jul; 31(7):1291-9. PubMed ID: 26729319
[TBL] [Abstract][Full Text] [Related]
66. FoxP3 and IDO in Canine Melanocytic Tumors.
Porcellato I; Brachelente C; De Paolis L; Menchetti L; Silvestri S; Sforna M; Vichi G; Iussich S; Mechelli L
Vet Pathol; 2019 Mar; 56(2):189-199. PubMed ID: 30381008
[TBL] [Abstract][Full Text] [Related]
67. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M
Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177
[TBL] [Abstract][Full Text] [Related]
68. Hepatitis B surface antigen as a marker for recurrent, metastatic hepatocellular carcinoma after liver transplantation.
Hshieh TT; Sundaram V; Najarian RM; Hanto DW; Karp SJ; Curry MP
Liver Transpl; 2012 Aug; 18(8):995-8. PubMed ID: 22829419
[No Abstract] [Full Text] [Related]
69. Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells.
Que Z; Zou F; Zhang A; Zheng Y; Bi L; Zhong J; Tian J; Liu J
Int Immunopharmacol; 2014 Nov; 23(1):192-204. PubMed ID: 25138378
[TBL] [Abstract][Full Text] [Related]
70. Kynurenine production mediated by indoleamine 2,3-dioxygenase aggravates liver injury in HBV-specific CTL-induced fulminant hepatitis.
Ohtaki H; Ito H; Ando K; Ishikawa T; Hoshi M; Ando T; Takamatsu M; Hara A; Moriwaki H; Saito K; Seishima M
Biochim Biophys Acta; 2014 Sep; 1842(9):1464-71. PubMed ID: 24768802
[TBL] [Abstract][Full Text] [Related]
71. The role of cytokines in hepatocellular carcinoma.
Budhu A; Wang XW
J Leukoc Biol; 2006 Dec; 80(6):1197-213. PubMed ID: 16946019
[TBL] [Abstract][Full Text] [Related]
72. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.
Monjazeb AM; Kent MS; Grossenbacher SK; Mall C; Zamora AE; Mirsoian A; Chen M; Kol A; Shiao SL; Reddy A; Perks JR; T N Culp W; Sparger EE; Canter RJ; Sckisel GD; Murphy WJ
Clin Cancer Res; 2016 Sep; 22(17):4328-40. PubMed ID: 26979392
[TBL] [Abstract][Full Text] [Related]
73. MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma.
Fiorino S; Bacchi-Reggiani ML; Visani M; Acquaviva G; Fornelli A; Masetti M; Tura A; Grizzi F; Zanello M; Mastrangelo L; Lombardi R; Di Tommaso L; Bondi A; Sabbatani S; Domanico A; Fabbri C; Leandri P; Pession A; Jovine E; de Biase D
World J Gastroenterol; 2016 Apr; 22(15):3907-36. PubMed ID: 27099435
[TBL] [Abstract][Full Text] [Related]
74. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma.
Ryu HS; Park YS; Park HJ; Chung YR; Yom CK; Ahn SH; Park YJ; Park SH; Park SY
Thyroid; 2014 Aug; 24(8):1232-40. PubMed ID: 24742251
[TBL] [Abstract][Full Text] [Related]
75. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
76. Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas.
Laimer K; Troester B; Kloss F; Schafer G; Obrist P; Perathoner A; Laimer J; Brandacher G; Rasse M; Margreiter R; Amberger A
Oral Oncol; 2011 May; 47(5):352-7. PubMed ID: 21440489
[TBL] [Abstract][Full Text] [Related]
77. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.
Shimoda M; Ghobrial RM; Carmody IC; Anselmo DM; Farmer DG; Yersiz H; Chen P; Dawson S; Durazo F; Han S; Goldstein LI; Saab S; Hiatt J; Busuttil RW
Liver Transpl; 2004 Dec; 10(12):1478-86. PubMed ID: 15558585
[TBL] [Abstract][Full Text] [Related]
78. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma.
Shen X; Li N; Li H; Zhang T; Wang F; Li Q
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1745-54. PubMed ID: 20221638
[TBL] [Abstract][Full Text] [Related]
79. Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels.
Jiang GM; He YW; Fang R; Zhang G; Zeng J; Yi YM; Zhang S; Bu XZ; Cai SH; Du J
Int J Biochem Cell Biol; 2010 Nov; 42(11):1840-6. PubMed ID: 20691806
[TBL] [Abstract][Full Text] [Related]
80. Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.
Johnson TS; Mcgaha T; Munn DH
Adv Exp Med Biol; 2017; 1036():91-104. PubMed ID: 29275467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
